Principles and Practice of Clinical Bacteriology Second Edition - Free

More documents

Recommendations

Info

Section One Gram-Positive Cocci
Page 1: Principles and Practice of Clinical
Page 5 and 6: Principles and Practice of Clinical
Page 7 and 8: Contents List of Contributors Prefa
Page 9 and 10: List of Contributors Dlawer A. A. A
Page 11: Preface Change is inevitable and no
Page 16 and 17: 4 β-HAEMOLYTIC STREPTOCOCCI Table
Page 18 and 19: 6 β-HAEMOLYTIC STREPTOCOCCI such a
Page 20 and 21: 8 β-HAEMOLYTIC STREPTOCOCCI Trends
Page 26 and 27: 14 β-HAEMOLYTIC STREPTOCOCCI isola
Page 28 and 29: 16 β-HAEMOLYTIC STREPTOCOCCI (Kotl
Page 30 and 31: 18 β-HAEMOLYTIC STREPTOCOCCI HPA (
Page 32 and 33: 20 β-HAEMOLYTIC STREPTOCOCCI Valdi
Page 34 and 35: 22 ORAL AND OTHER NON-β-HAEMOLYTIC
Page 53 and 54: 3 Streptococcus pneumoniae Indran B
Page 55 and 56: PATHOGENICITY 43 CbpA may act as a
Page 57 and 58: PATHOGENICITY 45 PC is of considera
Page 59 and 60: LABORATORY DIAGNOSIS 47 stain exami
Page 61 and 62: LABORATORY DIAGNOSIS 49 Table 3.5 A
Page 63 and 64:
LABORATORY DIAGNOSIS 51 transfer of
Page 65 and 66:
PREVENTION AND CONTROL 53 PREVENTIO
Page 67 and 68:
REFERENCES 55 Garcia-Bustos J, Toma
Page 69:
REFERENCES 57 Watson DA, Musher DM,
Page 72 and 73:
60 ENTEROCOCCUS SPP. pyrrolidonylar
Page 74 and 75:
62 ENTEROCOCCUS SPP. at least in pa
Page 76 and 77:
64 ENTEROCOCCUS SPP. et al., 2002).
Page 78 and 79:
66 ENTEROCOCCUS SPP. minocycline-re
Page 80 and 81:
68 ENTEROCOCCUS SPP. therapy of ent
Page 82 and 83:
70 ENTEROCOCCUS SPP. Hancock, L. E.
Page 85 and 86:
5 Staphylococcus aureus Sharon Peac
Page 87 and 88:
CELLULAR AND SECRETED COMPONENTS 75
Page 89 and 90:
GENETIC EXCHANGE 77 in exponential
Page 91 and 92:
79 Aminoglycoside phosphotransferas
Page 93 and 94:
STAPHYLOCOCCUS AUREUS AND THE HUMAN
Page 95 and 96:
CLINICAL SYNDROMES OF S. AUREUS DIS
Page 97 and 98:
LABORATORY ISOLATION AND IDENTIFICA
Page 99 and 100:
PREVENTION AND CONTROL 87 Guideline
Page 101 and 102:
REFERENCES 89 ClfA has had mixed re
Page 103 and 104:
REFERENCES 91 Staphylococcus aureus
Page 105 and 106:
REFERENCES 93 Kahl, B., Herrmann, M
Page 107 and 108:
REFERENCES 95 Novick, R.P., Schliev
Page 109 and 110:
REFERENCES 97 Stiles, B.G., Garza,
Page 111 and 112:
6 Coagulase-Negative Staphylococci
Page 113 and 114:
101 Table 6.2 (Continued) S. cohnii
Page 115 and 116:
EPIDEMIOLOGY 103 nutrient and is as
Page 117 and 118:
LABORATORY DIAGNOSIS 105 infections
Page 119 and 120:
MANAGEMENT OF INFECTION 107 complic
Page 121 and 122:
REFERENCES 109 Prolonged antibiotic
Page 123:
REFERENCES 111 Swan-Ganz catheters:
Page 127 and 128:
7 Corynebacterium spp. Aruni De Zoy
Page 129 and 130:
EPIDEMIOLOGY 117 cells of an animal
Page 131 and 132:
CLINICAL MANIFESTATIONS 119 associa
Page 133 and 134:
LABORATORY DIAGNOSIS OF DIPHTHERIA
Page 135 and 136:
OTHER POTENTIALLY TOXIGENIC CORYNEB
Page 137 and 138:
REFERENCES 125 a strict aerobe, wit
Page 139 and 140:
REFERENCES 127 Howard, W.T. (1893)
Page 141 and 142:
8 Listeria and Erysipelothrix spp.
Page 143 and 144:
EPIDEMIOLOGY 131 factors associated
Page 145 and 146:
LABORATORY DIAGNOSIS 133 Bacteraemi
Page 147 and 148:
EPIDEMIOLOGY 135 immunosuppression.
Page 149 and 150:
REFERENCES 137 REFERENCES Anon. (20
Page 151 and 152:
9 Bacillus spp. and Related Genera
Page 153 and 154:
DESCRIPTIONS OF ORGANISMS 141 (a) (
Page 155 and 156:
DESCRIPTIONS OF ORGANISMS 143 (a) (
Page 157 and 158:
NORMAL HABITATS 145 with spreading
Page 159 and 160:
EPIDEMIOLOGY 147 EPIDEMIOLOGY Bacil
Page 161 and 162:
CLINICAL FEATURES 149 (a) (b) Figur
Page 163 and 164:
LABORATORY DIAGNOSIS 151 LABORATORY
Page 165 and 166:
ANTIMICROBIAL SENSITIVITY AND MANAG
Page 167 and 168:
REFERENCES 155 vaccines in most par
Page 169 and 170:
REFERENCES 157 Logan NA, Forsyth G,
Page 171 and 172:
10 Mycobacterium tuberculosis Steph
Page 173 and 174:
CLINICAL FEATURES 161 symptom (Bann
Page 175 and 176:
LABORATORY DIAGNOSIS 163 by therapy
Page 177 and 178:
TREATMENT 165 mutations are constan
Page 179 and 180:
REFERENCES 167 reaction. This react
Page 181:
REFERENCES 169 Wilson, T. M., De Li
Page 184 and 185:
172 NON-TUBERCULOSIS MYCOBACTERIA T
Page 186 and 187:
174 NON-TUBERCULOSIS MYCOBACTERIA a
Page 188 and 189:
176 NON-TUBERCULOSIS MYCOBACTERIA i
Page 190 and 191:
178 NON-TUBERCULOSIS MYCOBACTERIA M
Page 192 and 193:
180 NON-TUBERCULOSIS MYCOBACTERIA H
Page 195 and 196:
12 Aerobic Actinomycetes Stephen H.
Page 197 and 198:
LABORATORY DIAGNOSIS 185 more virul
Page 199 and 200:
REFERENCES 187 Actinomadura is one
Page 201:
Section Three Gram-Negative Organis
Page 204 and 205:
192 MORAXELLA CATARRHALIS AND KINGE
Page 206 and 207:
Page 208 and 209:
Page 210 and 211:
Page 212 and 213:
Page 214 and 215:
Page 216 and 217:
Page 218 and 219:
206 NEISSERIA MENINGITIDIS of these
Page 220 and 221:
208 NEISSERIA MENINGITIDIS changing
Page 222 and 223:
210 NEISSERIA MENINGITIDIS but surf
Page 224 and 225:
212 NEISSERIA MENINGITIDIS can be m
Page 226 and 227:
214 NEISSERIA MENINGITIDIS identifi
Page 228 and 229:
216 NEISSERIA MENINGITIDIS PREVENTI
Page 230 and 231:
218 NEISSERIA MENINGITIDIS Outer Me
Page 232 and 233:
220 NEISSERIA MENINGITIDIS Makras,
Page 234 and 235:
222 NEISSERIA GONORRHOEAE Infection
Page 236 and 237:
224 NEISSERIA GONORRHOEAE Figure 15
Page 238 and 239:
226 NEISSERIA GONORRHOEAE hence, th
Page 240 and 241:
228 NEISSERIA GONORRHOEAE technical
Page 242 and 243:
230 NEISSERIA GONORRHOEAE Schwebke,
Page 244 and 245:
f 232 Table 16.1 Major properties f
Page 246 and 247:
234 ACINETOBACTER SPP. Table 16.2 C
Page 248 and 249:
236 ACINETOBACTER SPP. Skin and Sof
Page 250 and 251:
238 ACINETOBACTER SPP. Aminoglycosi
Page 252 and 253:
240 ACINETOBACTER SPP. Five other F
Page 254 and 255:
242 ACINETOBACTER SPP. Brisse S, Mi
Page 256 and 257:
244 ACINETOBACTER SPP. Rosenberg M,
Page 258 and 259:
246 HAEMOPHILUS SPP. 100 H. paraphr
Page 260 and 261:
248 HAEMOPHILUS SPP. Cases per 100
Page 262 and 263:
250 HAEMOPHILUS SPP. OTHER HAEMOPHI
Page 265 and 266:
18 Bordetella spp. Qiushui He 1 , J
Page 267 and 268:
PATHOGENESIS 255 PATHOGENESIS The p
Page 269 and 270:
LABORATORY DIAGNOSIS 257 adults ran
Page 271 and 272:
PREVENTION AND CONTROL 259 Pulsed-F
Page 273 and 274:
REFERENCES 261 Andrews, R., Herceg,
Page 275 and 276:
REFERENCES 263 Long, S.S. (1997) Bo
Page 277 and 278:
19 Brucella spp. Edward J. Young De
Page 279 and 280:
267 Table 19.3 Oxidative metabolism
Page 281 and 282:
LABORATORY DIAGNOSIS 269 of neurobr
Page 283:
REFERENCES 271 Goldstein, J., Hoffm
Page 286 and 287:
274 ACTINOBACILLUS ACTINOMYCETEMCOM
Page 288 and 289:
Page 290 and 291:
Page 293 and 294:
21 Francisella tularensis Petra C.
Page 295 and 296:
REFERENCES 283 10 days or streptomy
Page 297 and 298:
22 Rickettsia spp. James G. Olson 1
Page 299 and 300:
CLINICAL AND EPIDEMIOLOGICAL FEATUR
Page 301 and 302:
LABORATORY DIAGNOSIS 289 Table 22.3
Page 303 and 304:
LABORATORY DIAGNOSIS 291 before ino
Page 305 and 306:
REFERENCES 293 Chen, S.-M., Dumler,
Page 307 and 308:
23 Bartonella spp. J. M. Rolain and
Page 309 and 310:
CLINICAL FEATURES 297 In vivo, B. b
Page 311 and 312:
DIAGNOSIS 299 (xenodiagnosis). Thes
Page 313 and 314:
REFERENCES 301 infection. Treatment
Page 315 and 316:
REFERENCES 303 Maurin M, Eb F, Etie
Page 317 and 318:
24 Mycoplasma spp. Christiane Béb
Page 319 and 320:
PATHOGENESIS 307 23 to 40%. With th
Page 321 and 322:
DIAGNOSTIC METHODS 309 BV may lead
Page 323 and 324:
DIAGNOSTIC METHODS 311 Isolation of
Page 325 and 326:
TREATMENT, PREVENTION AND CONTROL 3
Page 327:
REFERENCES 315 Ieven M., Ursi D., V
Page 330 and 331:
318 CHLAMYDIA SPP. AND RELATED ORGA
Page 332 and 333:
Page 334 and 335:
Page 336 and 337:
Page 338 and 339:
Page 340 and 341:
Page 342 and 343:
330 TROPHERYMA WHIPPLEI different a
Page 344 and 345:
332 TROPHERYMA WHIPPLEI Nucleotides
Page 346 and 347:
334 TROPHERYMA WHIPPLEI The granulo
Page 348 and 349:
336 TROPHERYMA WHIPPLEI and Shorter
Page 350 and 351:
338 TROPHERYMA WHIPPLEI Altwegg, M.
Page 352 and 353:
340 TROPHERYMA WHIPPLEI Varvöli, C
Page 354 and 355:
342 IDENTIFICATION OF ENTEROBACTERI
Page 356 and 357:
344 Table 27.3 (Continued) Species
Page 359 and 360:
28 Escherichia coli and Shigella sp
Page 361 and 362:
PATHOTYPES OF E. COLI AND CLINICAL
Page 363 and 364:
Page 365 and 366:
Page 367 and 368:
LABORATORY METHODS FOR ISOLATION AN
Page 369 and 370:
PATHOGENESIS 357 Shigellae do not s
Page 371 and 372:
INFECTION CONTROL 359 Providencia,
Page 373 and 374:
REFERENCES 361 Blanco, J., Blanco,
Page 375 and 376:
REFERENCES 363 Marcato, P., Mulvey,
Page 377:
REFERENCES 365 Wullt, B. (2003) “
Page 380 and 381:
368 SALMONELLA SPP. Intracellular S
Page 382 and 383:
370 SALMONELLA SPP. animal reservoi
Page 384 and 385:
372 SALMONELLA SPP. German Ohne hau
Page 386 and 387:
374 SALMONELLA SPP. CVD906 and CVD9
Page 388 and 389:
376 SALMONELLA SPP. PHLS. (1999) Th
Page 390 and 391:
378 KLEBSIELLA, CITROBACTER, ENTERO
Page 392 and 393:
Page 394 and 395:
Page 396 and 397:
Page 398 and 399:
Page 400 and 401:
388 DONOVANOSIS AND KLEBSIELLA SPP.
Page 403 and 404:
32 Proteus, Providencia and Morgane
Page 405 and 406:
EPIDEMIOLOGICAL TYPING METHODS 393
Page 407 and 408:
REFERENCES 395 responsible (Neuwirt
Page 409 and 410:
33 Yersinia spp. M. B. Prentice Dep
Page 411 and 412:
PATHOGENICITY 399 associated with a
Page 413 and 414:
CLINICAL FEATURES 401 Factors in En
Page 415 and 416:
PREVENTION AND CONTROL 403 Table 33
Page 417 and 418:
REFERENCES 405 Inglesby, T. V., Den
Page 419 and 420:
34 Vibrio spp. Tom Cheasty Laborato
Page 421 and 422:
PATHOGENESIS OF CHOLERA 409 the hum
Page 423 and 424:
EPIDEMIOLOGY OF CHOLERA 411 produce
Page 425 and 426:
LABORATORY DIAGNOSIS 413 If the pre
Page 427 and 428:
PREVENTION AND CONTROL 415 to rehyd
Page 429:
REFERENCES 417 Hughes JM, Boyce JM,
Page 432 and 433:
420 AEROMONAS AND PLESIOMONAS SPP.
Page 434 and 435:
Page 436 and 437:
Page 438 and 439:
Page 440 and 441:
428 PSEUDOMONAS AND BURKHOLDERIA SP
Page 442 and 443:
Page 444 and 445:
Page 446 and 447:
Page 448 and 449:
Page 450 and 451:
Page 452 and 453:
Page 454 and 455:
Page 457 and 458:
37 Legionella spp. T. G. Harrison H
Page 459 and 460:
EPIDEMIOLOGY 447 Virulence Factors
Page 461 and 462:
CLINICAL FEATURES 449 the major out
Page 463 and 464:
DIAGNOSTIC METHODS 451 Table 37.2 S
Page 465 and 466:
REFERENCES 453 PREVENTION AND CONTR
Page 467 and 468:
REFERENCES 455 Hlady, W. G., Mullen
Page 469 and 470:
38 Coxiella burnetii James G. Olson
Page 471 and 472:
REFERENCES 459 More recently, green
Page 473:
Section Four Spiral Bacteria
Page 476 and 477:
464 LEPTOSPIRA SPP. Table 39.1 Spec
Page 478 and 479:
466 LEPTOSPIRA SPP. appearance of a
Page 480 and 481:
468 LEPTOSPIRA SPP. MAT titers (a)
Page 482 and 483:
470 LEPTOSPIRA SPP. Harkin, K. R.,
Page 485 and 486:
40 Helicobacter spp. and Related Or
Page 487 and 488:
GENE REGULATION 475 themselves infe
Page 489 and 490:
PATHOGENESIS 477 Meyer, 2000) and i
Page 491 and 492:
TREATMENT OF H. PYLORI 479 (EIA), w
Page 493 and 494:
REFERENCES 481 De Ungria MC, Kolesn
Page 495:
REFERENCES 483 Suerbaum S, Smith JM
Page 498 and 499:
486 CAMPYLOBACTER AND ARCOBACTER SP
Page 500 and 501:
Page 502 and 503:
Page 504 and 505:
Page 506 and 507:
Page 508 and 509:
Page 510 and 511:
Page 512 and 513:
Page 514 and 515:
Page 516 and 517:
504 TREPONEMES human host (Norris a
Page 518 and 519:
506 TREPONEMES are less likely to r
Page 520 and 521:
508 TREPONEMES standardised and is
Page 522 and 523:
510 TREPONEMES Parish JL (2000) Tre
Page 524 and 525:
512 BORRELIA SPP. Benach, 1989), 60
Page 526 and 527:
514 BORRELIA SPP. Furthermore, it m
Page 528 and 529:
516 BORRELIA SPP. While most patien
Page 530 and 531:
518 BORRELIA SPP. such patients (No
Page 532 and 533:
520 BORRELIA SPP. ‘chronic Lyme d
Page 534 and 535:
522 BORRELIA SPP. Dressler F, Whale
Page 536 and 537:
524 BORRELIA SPP. Qiu WG, Dykhuizen
Page 539:
Section Five Obligate Anaerobic Bac
Page 542 and 543:
530 ANAEROBIC COCCI Table 44.1 Chan
Page 544 and 545:
532 Table 44.2 Differential charact
Page 546 and 547:
534 ANAEROBIC COCCI morphology are
Page 548 and 549:
536 ANAEROBIC COCCI L can trigger t
Page 550 and 551:
538 ANAEROBIC COCCI seven species,
Page 552 and 553:
540 ANAEROBIC COCCI Soper DE, Brock
Page 554 and 555:
542 NON-SPORING GRAM-NEGATIVE ANAER
Page 556 and 557:
Page 558 and 559:
Page 560 and 561:
Page 562 and 563:
Page 564 and 565:
Page 566 and 567:
Page 568 and 569:
Page 570 and 571:
558 CLOSTRIDIUM DIFFICILE PATHOGENI
Page 572 and 573:
560 CLOSTRIDIUM DIFFICILE 1998). Th
Page 574 and 575:
562 CLOSTRIDIUM DIFFICILE stools ma
Page 576 and 577:
564 CLOSTRIDIUM DIFFICILE Lucet et
Page 578 and 579:
566 CLOSTRIDIUM DIFFICILE Verity P,
Page 580 and 581:
568 OTHER CLOSTRIDIUM SPP. Overview
Page 582 and 583:
570 OTHER CLOSTRIDIUM SPP. Clostrid
Page 584 and 585:
572 OTHER CLOSTRIDIUM SPP. were rep
Page 586 and 587:
574 OTHER CLOSTRIDIUM SPP. Barnham
Page 588 and 589:
576 ANAEROBIC ACTINOMYCETES AND REL
Page 590 and 591:
Page 592 and 593:
Page 594 and 595:
Page 596 and 597:
Page 598 and 599:
Page 600 and 601:
588 INDEX Aeromonas (Continued) gen
Page 602 and 603:
590 INDEX Bordetella pertussis (Con
Page 604 and 605:
592 INDEX Citrobacter koseri 382 Ci
Page 606 and 607:
594 INDEX Erythromycin in Actinomyc
Page 608 and 609:
596 INDEX Intestinal infectious dis
Page 610 and 611:
598 INDEX Mycobacterium branderi 17
Page 612 and 613:
600 INDEX Pertussis (Continued) imm
Page 614 and 615:
INDEX 601 Q fever 457 clinical feat
Page 616 and 617:
INDEX 603 mutans group 35 salivariu
show all

Principles and Practice of Clinical Bacteriology Second Edition - Free

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?